JP2021513077A5 - - Google Patents

Info

Publication number
JP2021513077A5
JP2021513077A5 JP2020542645A JP2020542645A JP2021513077A5 JP 2021513077 A5 JP2021513077 A5 JP 2021513077A5 JP 2020542645 A JP2020542645 A JP 2020542645A JP 2020542645 A JP2020542645 A JP 2020542645A JP 2021513077 A5 JP2021513077 A5 JP 2021513077A5
Authority
JP
Japan
Prior art keywords
dementia
subject
adm
level
adrenomedullin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513077A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/052982 external-priority patent/WO2019154900A1/en
Publication of JP2021513077A publication Critical patent/JP2021513077A/ja
Publication of JP2021513077A5 publication Critical patent/JP2021513077A5/ja
Priority to JP2023174585A priority Critical patent/JP2024001208A/ja
Pending legal-status Critical Current

Links

JP2020542645A 2018-02-08 2019-02-07 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー Pending JP2021513077A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174585A JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18155682 2018-02-08
EP18155682.0 2018-02-08
PCT/EP2019/052982 WO2019154900A1 (en) 2018-02-08 2019-02-07 Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174585A Division JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Publications (2)

Publication Number Publication Date
JP2021513077A JP2021513077A (ja) 2021-05-20
JP2021513077A5 true JP2021513077A5 (cg-RX-API-DMAC7.html) 2022-08-04

Family

ID=61188647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542645A Pending JP2021513077A (ja) 2018-02-08 2019-02-07 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー
JP2023174585A Pending JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174585A Pending JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および/または予測のためのアドレノメデュリン(adm)、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Country Status (12)

Country Link
US (2) US20210302440A1 (cg-RX-API-DMAC7.html)
EP (1) EP3749959A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021513077A (cg-RX-API-DMAC7.html)
KR (1) KR102717599B1 (cg-RX-API-DMAC7.html)
CN (2) CN119770645A (cg-RX-API-DMAC7.html)
AU (1) AU2019219071A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020014940A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090736A1 (cg-RX-API-DMAC7.html)
IL (1) IL276564A (cg-RX-API-DMAC7.html)
MX (1) MX421834B (cg-RX-API-DMAC7.html)
SG (1) SG11202006686SA (cg-RX-API-DMAC7.html)
WO (1) WO2019154900A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4110372A1 (en) * 2020-02-26 2023-01-04 PAM Theragnostics GmbH Use of peptidylglycine alpha-amidating monooxygenase (pam) for therapeutic purpose
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
JP2023515981A (ja) 2020-02-26 2023-04-17 ペーアーエム セラノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ペプチジルグリシンαアミド化モノオキシゲナーゼ(PAM)を決定する方法および診断目的でのその使用
US20210285949A1 (en) 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
EP4680966A1 (en) 2023-03-17 2026-01-21 PAM Theragnostics GmbH Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose
WO2025133203A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)
WO2026099249A1 (en) 2024-11-05 2026-05-15 Pam Theragnostics Gmbh Modified and unmodified peptidylglycine alpha-amidating monooxygenase (pam) for use in subjects having increased amyloid-beta and/or phospho-tau-protein load and/or neuroinflammation
WO2026099243A1 (en) 2024-11-05 2026-05-15 Pam Theragnostics Gmbh Modified and unmodified peptidyl-glycine alpha-amidating monooxygenase (pam) for use in the treatment or prevention of cerebral hypoperfusion for the improvement of cerebral blood flow (cbf)
WO2026132535A1 (en) 2024-12-20 2026-06-25 B.R.A.H.M.S Gmbh Pro-adrenomedullin and fragment(s) thereof for diagnosis and/or prognosis of a central nervous system inflammation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
US20090306227A1 (en) 2005-08-31 2009-12-10 Toshiyuki Ioka Tablet for removing tongue coating
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
WO2009095454A2 (de) * 2008-02-01 2009-08-06 Brahms Aktiengesellschaft Verfahren zur identifizierung von therapiebedürftigen patienten mit leichten kognitiven störungen und die behandlung derartiger patienten
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
BR112014011670B1 (pt) * 2011-11-16 2021-05-25 Adrenomed Ag anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou um arcabouço de proteína não-igg anti-adm que se liga à adrenomedulina e formulação farmacêutica
US9140696B2 (en) 2011-11-16 2015-09-22 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
US20160230227A1 (en) * 2012-12-21 2016-08-11 The New York Stem Cell Foundation Methods of treating alzheimer's disease
CN109716136B (zh) * 2016-07-08 2023-09-22 斯弗因高泰克有限公司 肾上腺髓质素用于评估急性心力衰竭患者的充血

Similar Documents

Publication Publication Date Title
JP2024001208A5 (cg-RX-API-DMAC7.html)
US12286480B2 (en) Modulators of ROR1-ROR2 binding
Chanez et al. Corticosteroid reversibility in COPD is related to features of asthma.
Dropcho Antiamphiphysin antibodies with small‐cell lung carcinoma and paraneoplastic encephalomyelitis
JP6457463B2 (ja) 処置方法
JP2016536332A5 (cg-RX-API-DMAC7.html)
JP2019533807A5 (cg-RX-API-DMAC7.html)
Yamaguchi et al. Enzyme‐linked immunosorbent assay of Pro‐gastrin‐releasing peptide for small cell lung cancer patients in comparison with neuron‐specific enolase measurement
WO2009038689A4 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
JP2008535494A5 (cg-RX-API-DMAC7.html)
JP2017501977A (ja) 肺高血圧症を治療するための組成物および方法
JP2017509692A5 (cg-RX-API-DMAC7.html)
CN115976196B (zh) ErbB3作为肺动脉高压生物标志物和治疗靶点的应用
CN110320368A (zh) 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
JP2024533873A5 (cg-RX-API-DMAC7.html)
EP4592679A1 (en) Use of discoidin domain receptor 2 in diagnosis of neurodegenerative diseases, and related computer readable medium
JP3095784B2 (ja) 炎症プロセスの病因を決定するための診断方法
WO2016065877A1 (zh) Cd166作为肝癌诊断血清标志物的应用及其试剂盒
KR102592460B1 (ko) 폐동맥고혈압 동물모델 및 이를 이용한 폐동맥고혈압 예방 또는 치료용 물질의 스크리닝 방법
JP2023544620A5 (cg-RX-API-DMAC7.html)
CN118203565A (zh) 去甲替林治疗纤维化疾病的药物用途
CN120285174A (zh) 抗vegf抗体与parp抑制剂联合用于治疗肿瘤
WO2021221668A1 (en) Anti-sars-cov-2 monoclonal antibody compositions
WO2024090571A1 (ja) Mmp12を指標とした免疫介在性炎症性疾患の診断、及びmmp12阻害による免疫介在性炎症性疾患の治療用医薬
WO2024154832A1 (ja) 全身性強皮症の検出方法